<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Thromb J</journal-id><journal-id journal-id-type="iso-abbrev">Thromb J</journal-id><journal-title-group><journal-title>Thrombosis Journal</journal-title></journal-title-group><issn pub-type="epub">1477-9560</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29299030</article-id><article-id pub-id-type="pmc">5745972</article-id><article-id pub-id-type="publisher-id">153</article-id><article-id pub-id-type="doi">10.1186/s12959-017-0153-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3266-6467</contrib-id><name><surname>Horjen</surname><given-names>Anja Wiedswang</given-names></name><address><phone>+47 67 80 99 24</phone><email>awhorjen@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Seljeflot</surname><given-names>Ingebj&#x000f8;rg</given-names></name><address><email>UXINLJ@ous-hf.no</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Berge</surname><given-names>Trygve</given-names></name><address><email>tryber@vestreviken.no</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>P&#x000e5;l</given-names></name><address><email>pal.smith@medisin.uio.no</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Arnesen</surname><given-names>Harald</given-names></name><address><email>UXHAAR@ous-hf.no</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tveit</surname><given-names>Arnljot</given-names></name><address><email>arnljot.tveit@vestreviken.no</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0389 7802</institution-id><institution-id institution-id-type="GRID">grid.459157.b</institution-id><institution>Department of Medical Research, B&#x000e6;rum Hospital, Vestre Viken Hospital Trust, </institution></institution-wrap>N-3004 Drammen, Norway </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8921</institution-id><institution-id institution-id-type="GRID">grid.5510.1</institution-id><institution>Faculty of Medicine, </institution><institution>University of Oslo, </institution></institution-wrap>Oslo, Norway </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0389 8485</institution-id><institution-id institution-id-type="GRID">grid.55325.34</institution-id><institution>Center for Clinical Heart Research, Department of Cardiology, </institution><institution>Oslo University Hospital Ullev&#x000e5;l, </institution></institution-wrap>Oslo, Norway </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9637 455X</institution-id><institution-id institution-id-type="GRID">grid.411279.8</institution-id><institution>Department of Cardiology, </institution><institution>Akershus University Hospital, </institution></institution-wrap>L&#x000f8;renskog, Norway </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>15</volume><elocation-id>30</elocation-id><history><date date-type="received"><day>6</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Atrial fibrillation (AF) confers a hypercoagulable state; however, it is not clear whether restoration of sinus rhythm is associated with normalisation of markers of thrombogenesis. We studied the impact of sustained sinus rhythm on prothrombotic markers, and their predictive abilities in foreseeing rhythm outcome after cardioversion.</p></sec><sec><title>Methods</title><p id="Par2">In a double blind, placebo-controlled study, 171 patients referred for electrical cardioversion of persistent AF were randomised to receive candesartan or placebo for 3-6&#x000a0;weeks before and 6&#x000a0;months after cardioversion. Endogenous thrombin potential (ETP), prothrombin fragment&#x000a0;1&#x02009;+&#x02009;2 (F1&#x02009;+&#x02009;2) and D-dimer were measured before cardioversion and at end of study. These markers were also measured in a reference group comprising 49 subjects without AF.</p></sec><sec><title>Results</title><p id="Par3">The markers remained unchanged in those 28 patients who maintained sinus rhythm. Discontinuation of warfarin treatment in a subset of 13 low-risk patients in sinus rhythm was associated with significantly higher levels of D-dimer and F1&#x02009;+&#x02009;2 compared to the reference group; D-dimer (456&#x000a0;ng/mL (276, 763) vs. 279&#x000a0;ng/mL (192, 348), <italic>p</italic>&#x02009;=&#x02009;0.002) and F1&#x02009;+&#x02009;2 (700&#x000a0;pmol/L (345, 845) vs. 232&#x000a0;pmol/L (190, 281), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). None of the markers were associated with rhythm outcome after electrical cardioversion.</p></sec><sec><title>Conclusions</title><p id="Par4">Sustained sinus rhythm for 6&#x000a0;months after cardioversion for AF had no impact on ETP, F1&#x02009;+&#x02009;2 or D-dimer levels. Discontinuation of warfarin in low-risk patients with sustained sinus rhythm was associated with significantly higher levels of D-dimer and F1&#x02009;+&#x02009;2 compared to the reference group. Our results suggest persistent hypercoagulability in AF patients despite long-term maintenance of sinus rhythm.</p></sec><sec><title>Trial registration</title><p id="Par5">The CAPRAF study was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT00130975) in August 2005.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Atrial fibrillation</kwd><kwd>Cardioversion</kwd><kwd>Hypercoagulability</kwd><kwd>Thrombin generation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011338</institution-id><institution>AstraZeneca Schweiz</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>Regional Health Corporation of Eastern Norway</institution></funding-source></award-group><award-group><funding-source><institution>Medical Research Foundation, B&#x000e6;rum hospital</institution></funding-source></award-group><award-group><funding-source><institution>Vestre Viken Hospital Trust</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par15">Atrial fibrillation (AF) is a major risk factor for thromboembolic events [<xref ref-type="bibr" rid="CR1">1</xref>]. The hypercoagulability in AF is related to blood stasis, endocardial changes and abnormal blood constituents including increased markers of thrombogenesis [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. The prothrombotic state in AF is adversely affected by electrical cardioversion [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], and current guidelines recommend that anticoagulation should be continued lifelong in patients with risk factors of stroke or AF recurrence, irrespective of apparent maintenance of sinus rhythm following cardioversion [<xref ref-type="bibr" rid="CR7">7</xref>]. Whether the activation of the coagulation system persists or is attenuated after prolonged periods of sinus rhythm, remains an open question.</p><p id="Par16">Haemostatic alterations as a consequence of AF are widely accepted. Intriguingly, it has recently been suggested that hypercoagulability in itself causes atrial fibrosis and thereby promotes a substrate for AF [<xref ref-type="bibr" rid="CR8">8</xref>]. AF is associated with elevated levels of prothrombin fragment&#x000a0;1&#x02009;+&#x02009;2 (F1&#x02009;+&#x02009;2) [<xref ref-type="bibr" rid="CR9">9</xref>]. F1&#x02009;+&#x02009;2 is released during the conversion of prothrombin to thrombin, whereas the endogenous thrombin potential (ETP) indicates an ex vivo potential for thrombin generation. Measurement of D-dimer reflects both thrombin generation and fibrin turnover, and may complement clinical and echocardiographic risk stratification for stroke and thromboembolism in AF [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The predictive abilities of ETP, F1&#x02009;+&#x02009;2 and D-dimer in foreseeing rhythm outcome after electrical cardioversion for AF have not previously been reported.</p><p id="Par17">The objectives of the present investigation were twofold. First, to study the effects of sustained sinus rhythm after electrical cardioversion on levels of ETP, F1&#x02009;+&#x02009;2 and D-dimer, and to compare these markers in low-risk AF patients in sinus rhythm with levels measured in a reference group without AF. Secondly, we evaluated the prognostic abilities of ETP, F1&#x02009;+&#x02009;2 and D-dimer in foreseeing rhythm outcome 6 months after electrical cardioversion.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par18">The present study is a substudy of the double blind, placebo-controlled Candesartan in the Prevention of Relapsing Atrial Fibrillation (CAPRAF) study [<xref ref-type="bibr" rid="CR13">13</xref>]. Briefly, 171 patients with AF were randomised to receive candesartan 8&#x000a0;mg once daily (<italic>n</italic>&#x02009;=&#x02009;86) or placebo (<italic>n</italic>&#x02009;=&#x02009;85) for 3 to 6 weeks before and then candesartan 16&#x000a0;mg once daily or placebo for 6 months after electrical cardioversion (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Patients with congestive heart failure or renal impairment were not included in the study. Cardioversion was deemed successful if sinus rhythm was established and maintained for at least 2 h (<italic>n</italic>&#x02009;=&#x02009;134). Relapse of AF was defined as first electrocardiogram&#x02013;recorded episode of AF. Blood samples were collected at baseline and at 6 months&#x02019; follow-up. CHA<sub>2</sub>DS<sub>2</sub>-VASc score was used to stratify patients according to risk of stroke, with scores ranging from 0 to 9 and higher scores indicating greater risk. The scoring system assigns one point for each of the following; congestive heart failure, hypertension, age 65-74&#x000a0;years, diabetes, vascular disease or female sex, whereas age&#x02009;&#x02265;&#x02009;75&#x000a0;years and previous stroke or transient ischemic attack count two points each. The study was approved by the Regional Ethics Committee, and all patients provided written, informed consent in accordance with the revised Declaration of Helsinki. The CAPRAF study is registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT00130975).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of the CAPRAF study and reference group recruited from the ACE 1950 study. Abbreviations: ACE, Akershus Cardiac Examination 1950 study; AF, atrial fibrillation; CAPRAF study, Candesartan in the Prevention of Relapsing Atrial Fibrillation study; n, number of patients; SR, sinus rhythm</p></caption><graphic xlink:href="12959_2017_153_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par19">Residents of Asker and B&#x000e6;rum municipalities participating in a pilot for the Akershus Cardiac Examination (ACE) 1950 study were included as reference group (<italic>n</italic>&#x02009;=&#x02009;49) [<xref ref-type="bibr" rid="CR14">14</xref>]. Fifty-one subjects accepted the invitation to this pilot. Two subjects were diagnosed with AF, and therefore excluded from the reference group (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Approval was obtained by the Regional Ethics Committee, and all patients provided written, informed consent in accordance with the revised Declaration of Helsinki. The ACE 1950 study is registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT01555411).</p></sec><sec id="Sec4"><title>Laboratory analyses</title><p id="Par20">After centrifugation, citrated plasma was aliquoted and kept frozen at &#x02212;70&#x000a0;&#x000b0;C until analysed. Levels of F1&#x02009;+&#x02009;2 and D-dimer were assessed by commercially available enzyme immunoassays; Enzygnost&#x000ae; F1&#x02009;+&#x02009;2 (monoclonal) (Siemens, Marburg, Germany) and Asserachrom&#x000ae; D-dimer (Stago Diagnostica). The coefficients of variation were 5.4% for F1&#x02009;+&#x02009;2 and 6.5% for D-dimer.</p><p id="Par21">Ex-vivo thrombin generation potential was investigated by the calibrated automated thrombogram (CAT) assay, performed according to the manufacturer&#x02019;s instruction (Thrombinoscope BV, Maastricht, The Netherlands). The method is described in detail elsewhere [<xref ref-type="bibr" rid="CR15">15</xref>]. Briefly, platelet poor plasma was mixed with a reagent containing relipidated tissue factor and phospholipids, with the final concentrations of 5 pM and 4&#x000a0;&#x003bc;M, respectively. Reagents were provided from Thrombinoscope BV (Maastricht, The Netherlands). The reactions were performed in micro titer wells after automatic addition of a fresh made starting reagent containing CaCl<sub>2</sub> (100&#x000a0;mM) and a thrombin specific fluorogenic substrate (Z-Gly-Gly-Arg-AMC) (2.5&#x000a0;mM). The fluorescence intensity was recorded by the Fluoroskan Ascent&#x000ae; micro plate fluorometer (Thermo Fisher Scientific Oy, Vantaa, Finland). By simultaneous analysis of an inert thrombin calibrator with known thrombin activity, the software program (Thrombinoscope BV, version 3.0.0.29) is enabled to display the ETP (nM*min). The coefficient of variation was 5.9% for ETP.</p></sec><sec id="Sec5"><title>Statistical analyses</title><p id="Par22">Data are presented as mean&#x02009;&#x000b1;&#x02009;standard deviation for normally distributed variables, while continuous variables not normally distributed are expressed as median (25<sup>th</sup>, 75<sup>th</sup> percentiles). Categorical variables are shown as frequencies (%). Continuous variables were analysed by Student <italic>t</italic> test or the Mann-Whitney <italic>U</italic>-test depending on distribution. Categorical data were compared by the Chi-square test or Fischer&#x02019;s exact test where appropriate. The impact of continuous clinical variables and CHA<sub>2</sub>DS<sub>2</sub>-VASc score on haemostatic markers was analysed using bivariate non-parametric correlations (Spearman, correlation coefficient denoted r<sub>s</sub>). Kaplan-Meier curves for the probability of first recurrence of AF were plotted for medians and quartiles of baseline levels of the haemostatic markers and compared by log-rank test. Group comparisons were assessed by Mann-Whitney <italic>U</italic>-test. Kruskal-Wallis H test was used to compare levels of the markers according to CHA<sub>2</sub>DS<sub>2</sub>-VASc risk groups. For pairwise comparisons Bonferroni adjusted Mann-Whitney <italic>U</italic>-test was used. Wilcoxon&#x02019;s matched-pairs test was used to compare baseline and end-of-study levels of the markers. The effects of treatment with candesartan and discontinued warfarin treatment on prothrombotic marker levels were assessed with ANCOVA regression analysis on logarithmically transformed data. To investigate the impact of potential confounders on the relation between AF and the prothrombotic markers, variables related to both AF and the haemostatic indices with a <italic>p</italic>-value of &#x0003c;&#x02009;0.20 were included in a multivariate linear regression model, with logarithmically transformed marker values as the dependent variable. Medications were not included in the multivariate analysis because they were thought only to reflect the diseases that indicated their use. A two-sided <italic>p</italic>-value of &#x0003c;&#x02009;0.05 was considered statistically significant. Statistical analyses were performed with IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., New York, USA).</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par23">Baseline levels of the prothrombotic markers were available in 134 (33 women/101 men) successfully cardioverted patients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The mean age was 64&#x02009;&#x000b1;&#x02009;11&#x000a0;years (range 21-84). The mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score of this population was 1.5&#x02009;&#x000b1;&#x02009;1.3 (range 0-5). The prothrombin time, expressed as the International Normalised Ratio (INR), was 2.3&#x02009;&#x000b1;&#x02009;0.7 at baseline.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the successfully cardioverted atrial fibrillation patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>
<italic>n</italic>&#x02009;=&#x02009;134</th></tr></thead><tbody><tr><td colspan="2">
<italic>Medical history</italic>
</td></tr><tr><td>&#x02003;Age (years)</td><td>64&#x02009;&#x000b1;&#x02009;11</td></tr><tr><td>&#x02003;Sex (women/men)</td><td>33/101</td></tr><tr><td>&#x02003;Body mass index (kg/m<sup>2</sup>)</td><td>26&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td>&#x02003;Hypertension</td><td>38 (28%)</td></tr><tr><td>&#x02003;Coronary heart disease</td><td>12 (9%)</td></tr><tr><td>&#x02003;Diabetes</td><td>10 (7%)</td></tr><tr><td>&#x02003;Chronic obstructive pulmonary disease</td><td>7 (5%)</td></tr><tr><td>&#x02003;Current cigarette smoking</td><td>21 (16%)</td></tr><tr><td>&#x02003;CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td>1.5&#x02009;&#x000b1;&#x02009;1.3</td></tr><tr><td colspan="2">
<italic>Medication at randomisation</italic>
</td></tr><tr><td>&#x02003;Angiotensin receptor blocker/study drug</td><td>66 (49%)</td></tr><tr><td>&#x02003;Digitalis</td><td>16 (12%)</td></tr><tr><td>&#x02003;Beta-blockers</td><td>48 (36%)</td></tr><tr><td>&#x02003;Calcium channel blockers</td><td>63 (47%)</td></tr><tr><td>&#x02003;Diuretics</td><td>11 (8%)</td></tr><tr><td>&#x02003;Statins</td><td>18 (13%)</td></tr><tr><td colspan="2">
<italic>Blood pressure and heart rate</italic>
</td></tr><tr><td>&#x02003;Systolic blood pressure (mmHg)</td><td>134&#x02009;&#x000b1;&#x02009;18</td></tr><tr><td>&#x02003;Diastolic blood pressure (mmHg)</td><td>82&#x02009;&#x000b1;&#x02009;8</td></tr><tr><td>&#x02003;Ventricular heart rate (beats per minute)</td><td>85&#x02009;&#x000b1;&#x02009;17</td></tr><tr><td colspan="2">
<italic>Echocardiographic assessments</italic>
</td></tr><tr><td>&#x02003;Left atrial systolic diameter (mm)</td><td>46&#x02009;&#x000b1;&#x02009;6</td></tr><tr><td>&#x02003;Left atrial systolic area (cm<sup>2</sup>)</td><td>27&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td>&#x02003;Fraction of shortening (%)</td><td>30&#x02009;&#x000b1;&#x02009;7</td></tr></tbody></table><table-wrap-foot><p>Baseline clinical characteristics of the 134 successfully cardioverted patients in the Candesartan in the Prevention of Relapsing Atrial Fibrillation (CAPRAF) study. Values presented as mean&#x02009;&#x000b1;&#x02009;standard deviation or number (%). <italic>Abbreviations</italic>: <italic>CHA</italic>
<sub><italic>2</italic></sub>
<italic>DS</italic>
<sub><italic>2</italic></sub>
<italic>-VASc score</italic> A measure of stroke risk in patients with atrial fibrillation, with scores ranging from 0 to 9 and higher scores indicating greater risk, <italic>n</italic> Number of patients</p></table-wrap-foot></table-wrap>
</p><p id="Par24">Median baseline levels of D-dimer (357&#x000a0;ng/mL (226, 524)) and F1&#x02009;+&#x02009;2 (190&#x000a0;pmol/L (140, 310)) have been reported previously [<xref ref-type="bibr" rid="CR16">16</xref>]. Median baseline level of ETP was 474&#x000a0;nM*min (366, 620). A correlation was seen between F1&#x02009;+&#x02009;2 and ETP (r<sub>s</sub>&#x02009;=&#x02009;0.594, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). D-dimer correlated to F1&#x02009;+&#x02009;2 (r<sub>s</sub>&#x02009;=&#x02009;0.479, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), but not to ETP (r<sub>s</sub>&#x02009;=&#x02009;0.151, <italic>p</italic>&#x02009;=&#x02009;0.087).</p><p id="Par25">D-dimer correlated to age (r<sub>s</sub>&#x02009;=&#x02009;0.331, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), left atrial area (r<sub>s</sub>&#x02009;=&#x02009;0.182, <italic>p</italic>&#x02009;=&#x02009;0.040) and left atrial diameter (r<sub>s</sub>&#x02009;=&#x02009;0.201, <italic>p</italic>&#x02009;=&#x02009;0.022) [<xref ref-type="bibr" rid="CR16">16</xref>]. Subjects with diabetes had higher levels of D-dimer; (491&#x000a0;ng/mL (290, 671) vs. 350&#x000a0;ng/mL (219, 500), <italic>p</italic>&#x02009;=&#x02009;0.045). Levels of F1&#x02009;+&#x02009;2 correlated to left atrial area (r<sub>s</sub>&#x02009;=&#x02009;0.183, <italic>p</italic>&#x02009;=&#x02009;0.039) and left atrial diameter (r<sub>s</sub>&#x02009;=&#x02009;0.193, <italic>p</italic>&#x02009;=&#x02009;0.028). Levels of ETP correlated to left atrial area (r<sub>s</sub>&#x02009;=&#x02009;0.181, <italic>p</italic>&#x02009;=&#x02009;0.042) and to body mass index (r<sub>s</sub>&#x02009;=&#x02009;0.194, <italic>p</italic>&#x02009;=&#x02009;0.032). Females had lower levels of ETP as compared to males; (436&#x000a0;nM*min (292, 526) vs. 493&#x000a0;nM*min (391, 623), <italic>p</italic>&#x02009;=&#x02009;0.035). CHA<sub>2</sub>DS<sub>2</sub>-VASc score correlated weakly, but significantly with baseline levels of D-dimer (r<sub>s</sub>&#x02009;=&#x02009;0.213, <italic>p</italic>&#x02009;=&#x02009;0.015). An inverse correlation was observed between CHA<sub>2</sub>DS<sub>2</sub>-VASc score and baseline levels of ETP (r<sub>s</sub>&#x02009;=&#x02009;&#x02212;0.215, <italic>p</italic>&#x02009;=&#x02009;0.014). Baseline levels of ETP were significantly higher in patients with low CHA<sub>2</sub>DS<sub>2</sub>-VASc score (0-1) as compared to patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score&#x02009;&#x02265;&#x02009;3; (534&#x000a0;nM*min (419, 705) vs. 417&#x000a0;nM*min (276, 539), <italic>p</italic>&#x02009;=&#x02009;0.011).</p><p id="Par26">In order to evaluate the potential impact of sustained sinus rhythm on levels of prothrombotic markers, baseline blood samples drawn before electrical cardioversion were compared with levels at study end in patients with 6 months&#x02019; survival-free of AF and with continued warfarin treatment throughout the study. The prothrombotic markers remained unchanged in the 28 patients with sustained sinus rhythm for 6 months and who were treated with warfarin till study end; D-dimer (367&#x000a0;ng/mL (271, 454) vs. 437&#x000a0;ng/mL (237, 572), <italic>p</italic>&#x02009;=&#x02009;0.809), F1&#x02009;+&#x02009;2 (195&#x000a0;pmol/L (140, 350) vs. 170&#x000a0;pmol/L (135, 240), <italic>p</italic>&#x02009;=&#x02009;0.056) and ETP (485&#x000a0;nM*min (392, 653) vs. 429&#x000a0;nM*min (362, 531), <italic>p</italic>&#x02009;=&#x02009;0.209) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Baseline levels of INR were comparable with study end levels; (2.3&#x02009;&#x000b1;&#x02009;0.8 vs. 2.4&#x02009;&#x000b1;&#x02009;0.5, <italic>p</italic>&#x02009;=&#x02009;0.914).<fig id="Fig2"><label>Fig. 2</label><caption><p>Marker levels in patients with sustained SR and continued warfarin treatment. <italic>P</italic>-values derived from the Wilcoxon signed-rank test. Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile range from the 25<sup>th</sup> and 75<sup>th</sup> percentiles. Abbreviations: ETP, endogenous thrombin potential; F1&#x02009;+&#x02009;2, prothrombin fragment&#x000a0;1&#x02009;+&#x02009;2; SR, sinus rhythm</p></caption><graphic xlink:href="12959_2017_153_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par27">Warfarin was discontinued in 13 AF patients after successful cardioversion (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). These patients were younger (59&#x02009;&#x000b1;&#x02009;12&#x000a0;years vs. 68&#x02009;&#x000b1;&#x02009;9&#x000a0;years, <italic>p</italic>&#x02009;=&#x02009;0.008), had a lower prevalence of hypertension (15% vs. 43%, <italic>p</italic>&#x02009;=&#x02009;0.156) and a lower CHA<sub>2</sub>DS<sub>2</sub>-VASc score (1.2&#x02009;&#x000b1;&#x02009;1.3 vs. 2.1&#x02009;&#x000b1;&#x02009;1.5, <italic>p</italic>&#x02009;=&#x02009;0.177) compared to those 28 AF patients who continued warfarin treatment (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The time interval between warfarin discontinuation and study end was 106&#x02009;&#x000b1;&#x02009;29&#x000a0;days (range 45-146). A significant rise in all markers was seen in the 13 patients who discontinued warfarin treatment; D-dimer (456&#x000a0;ng/mL (276, 763) vs. 304&#x000a0;ng/mL (165,470), <italic>p</italic>&#x02009;=&#x02009;0.002), F1&#x02009;+&#x02009;2 (700&#x000a0;pmol/L (345, 845) vs. 160&#x000a0;pmol/L (110, 190), <italic>p</italic>&#x02009;=&#x02009;0.034) and ETP (1279&#x000a0;nM*min (1069, 1496) vs. 417&#x000a0;nM*min (339, 494), <italic>p</italic>&#x02009;=&#x02009;0.001). ANCOVA analysis comparing the changes in prothrombotic markers from baseline to study end showed significant effects of discontinued warfarin treatment in the 13 low-risk AF patients; D-dimer (<italic>p</italic>&#x02009;=&#x02009;0.006), F1&#x02009;+&#x02009;2 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and ETP (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).<table-wrap id="Tab2"><label>Table 2</label><caption><p>AF patients in SR 6 months after cardioversion according to warfarin treatment at study end</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>No warfarin (<italic>n</italic>&#x02009;=&#x02009;13)</th><th>Warfarin (<italic>n</italic>&#x02009;=&#x02009;28)</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td colspan="4">
<italic>Medical history</italic>
</td></tr><tr><td>&#x02003;Age (years)</td><td>59&#x02009;&#x000b1;&#x02009;12</td><td>68&#x02009;&#x000b1;&#x02009;9</td><td>0.008</td></tr><tr><td>&#x02003;Sex (women/men)</td><td>4/9</td><td>6/22</td><td>0.698</td></tr><tr><td>&#x02003;Body mass index (kg/m<sup>2</sup>)</td><td>25&#x02009;&#x000b1;&#x02009;3</td><td>25&#x02009;&#x000b1;&#x02009;2</td><td>0.602</td></tr><tr><td>&#x02003;Hypertension</td><td>2 (15%)</td><td>12 (43%)</td><td>0.156</td></tr><tr><td>&#x02003;Coronary heart disease</td><td>1 (8%)</td><td>5 (18%)</td><td>0.645</td></tr><tr><td>&#x02003;Diabetes</td><td>1 (8%)</td><td>0</td><td>0.317</td></tr><tr><td>&#x02003;Chronic obstructive pulmonary disease</td><td>0</td><td>1 (4%)</td><td>1.0</td></tr><tr><td>&#x02003;Current cigarette smoking</td><td>3 (23%)</td><td>2 (7%)</td><td>0.307</td></tr><tr><td>&#x02003;CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td>1.2&#x02009;&#x000b1;&#x02009;1.3</td><td>2.1&#x02009;&#x000b1;&#x02009;1.5</td><td>0.177</td></tr><tr><td colspan="4">
<italic>Medication</italic>
</td></tr><tr><td>&#x02003;Angiotensin receptor blocker/study drug</td><td>6 (46%)</td><td>12 (43%)</td><td>0.843</td></tr><tr><td>&#x02003;Angiotensin-converting enzyme inhibitor</td><td>0</td><td>0</td><td>&#x02013;</td></tr><tr><td>&#x02003;Beta-blockers</td><td>3 (23%)</td><td>11 (39%)</td><td>0.481</td></tr><tr><td>&#x02003;Calcium channel blockers</td><td>3 (23%)</td><td>8 (29%)</td><td>1.0</td></tr><tr><td>&#x02003;Diuretics</td><td>0</td><td>2 (7%)</td><td>1.0</td></tr><tr><td>&#x02003;Statins</td><td>1 (8%)</td><td>9 (32%)</td><td>0.129</td></tr><tr><td>&#x02003;Antiplatelet therapy</td><td>2 (15%)</td><td>0</td><td>0.095</td></tr><tr><td colspan="4">
<italic>Blood pressure and heart rate</italic>
</td></tr><tr><td>&#x02003;Systolic blood pressure (mmHg)</td><td>129&#x02009;&#x000b1;&#x02009;18</td><td>140&#x02009;&#x000b1;&#x02009;17</td><td>0.060</td></tr><tr><td>&#x02003;Diastolic blood pressure (mmHg)</td><td>78&#x02009;&#x000b1;&#x02009;6</td><td>80&#x02009;&#x000b1;&#x02009;7</td><td>0.401</td></tr><tr><td>&#x02003;Ventricular heart rate (beats per minute)</td><td>59&#x02009;&#x000b1;&#x02009;7</td><td>58&#x02009;&#x000b1;&#x02009;14</td><td>0.857</td></tr></tbody></table><table-wrap-foot><p>Clinical characteristics of atrial fibrillation patients maintaining sinus rhythm for 6 months after electrical cardioversion with (<italic>n</italic>&#x02009;=&#x02009;28) and without (<italic>n</italic>&#x02009;=&#x02009;13) warfarin treatment. Values presented as mean&#x02009;&#x000b1;&#x02009;standard deviation or number (%). <italic>Abbreviations</italic>: <italic>AF</italic> Atrial fibrillation; CHA<sub>2</sub>DS<sub>2</sub>-VASc score, a measure of stroke risk in patients with atrial fibrillation, with scores ranging from 0 to 9 and higher scores indicating greater risk, <italic>n</italic> Number of patients, <italic>SR</italic> Sinus rhythm</p></table-wrap-foot></table-wrap>
</p><p id="Par28">Marker values in the 13 patients in sinus rhythm at end of study were compared with corresponding values of 49 subjects in the reference group (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In these 13 AF patients, D-dimer and F1&#x02009;+&#x02009;2 were significantly elevated compared to the reference group; D-dimer (456&#x000a0;ng/mL (276, 763) vs. 279&#x000a0;ng/mL (192, 348), <italic>p</italic>&#x02009;=&#x02009;0.002) and F1&#x02009;+&#x02009;2 (700&#x000a0;pmol/L (345, 845) vs. 232&#x000a0;pmol/L (190, 281), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). There were no significant differences in levels of ETP; (1279&#x000a0;nM*min (1069, 1496) vs. 1377&#x000a0;nM*min (1204, 1509), <italic>p</italic>&#x02009;=&#x02009;0.557) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Hypertension was the only variable that met our criteria for potential confounders. In multivariate, linear regression analysis, AF remained the only significant determinant of both markers; D-dimer (0.50 (0.15, 0.43), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, R<sup>2</sup>&#x02009;=&#x02009;0.25) and F1&#x02009;+&#x02009;2 (0.60 (0.22, 0.48), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, R<sup>2</sup>&#x02009;=&#x02009;0.36).<table-wrap id="Tab3"><label>Table 3</label><caption><p>AF patients in SR with discontinued warfarin treatment at study end versus the reference group</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>AF patients (<italic>n</italic>&#x02009;=&#x02009;13)</th><th>Reference group (<italic>n</italic>&#x02009;=&#x02009;49)</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td colspan="4">
<italic>Medical history</italic>
</td></tr><tr><td>&#x02003;Age (years)</td><td>59&#x02009;&#x000b1;&#x02009;12</td><td>62&#x02009;&#x000b1;&#x02009;0</td><td>0.298</td></tr><tr><td>&#x02003;Sex (women/men)</td><td>4/9</td><td>20/29</td><td>0.509</td></tr><tr><td>&#x02003;Body mass index (kg/m<sup>2</sup>)</td><td>25&#x02009;&#x000b1;&#x02009;3</td><td>26&#x02009;&#x000b1;&#x02009;4</td><td>0.253</td></tr><tr><td>&#x02003;Hypertension</td><td>2 (15%)</td><td>18 (37%)</td><td>0.192</td></tr><tr><td>&#x02003;Coronary heart disease</td><td>1 (8%)</td><td>2 (4%)</td><td>0.513</td></tr><tr><td>&#x02003;Diabetes</td><td>1 (8%)</td><td>4 (8%)</td><td>1.0</td></tr><tr><td>&#x02003;Chronic obstructive pulmonary disease</td><td>0</td><td>1 (2%)</td><td>1.0</td></tr><tr><td>&#x02003;Current cigarette smoking</td><td>3 (23%)</td><td>7 (14%)</td><td>0.432</td></tr><tr><td colspan="4">
<italic>Medication</italic>
</td></tr><tr><td>&#x02003;Angiotensin receptor blocker/study drug</td><td>6 (46%)</td><td>13 (27%)</td><td>0.192</td></tr><tr><td>&#x02003;Angiotensin-converting enzyme inhibitor</td><td>0</td><td>1 (2%)</td><td>1.0</td></tr><tr><td>&#x02003;Beta-blockers</td><td>3 (23%)</td><td>4 (8%)</td><td>0.153</td></tr><tr><td>&#x02003;Calcium channel blockers</td><td>3 (23%)</td><td>4 (8%)</td><td>0.153</td></tr><tr><td>&#x02003;Diuretics</td><td>0</td><td>4 (8%)</td><td>0.571</td></tr><tr><td>&#x02003;Statins</td><td>1 (8%)</td><td>11 (22%)</td><td>0.431</td></tr><tr><td>&#x02003;Antiplatelet therapy</td><td>2 (15%)</td><td>5 (10%)</td><td>0.630</td></tr><tr><td colspan="4">
<italic>Blood pressure and heart rate</italic>
</td></tr><tr><td>&#x02003;Systolic blood pressure (mmHg)</td><td>129&#x02009;&#x000b1;&#x02009;18</td><td>134&#x02009;&#x000b1;&#x02009;15</td><td>0.326</td></tr><tr><td>&#x02003;Diastolic blood pressure (mmHg)</td><td>78&#x02009;&#x000b1;&#x02009;6</td><td>78&#x02009;&#x000b1;&#x02009;8</td><td>0.779</td></tr><tr><td>&#x02003;Ventricular heart rate (beats per minute)</td><td>59&#x02009;&#x000b1;&#x02009;7</td><td>64&#x02009;&#x000b1;&#x02009;10</td><td>0.072</td></tr></tbody></table><table-wrap-foot><p>Clinical characteristics of atrial fibrillation patients maintaining sinus rhythm for 6 months without warfarin treatment at study end (<italic>n</italic>&#x02009;=&#x02009;13) versus the reference group (<italic>n</italic>&#x02009;=&#x02009;49).Values presented as mean&#x02009;&#x000b1;&#x02009;standard deviation or number (%). <italic>Abbreviations</italic>: <italic>AF</italic> Atrial fibrillation; <italic>n</italic> Number of patients, <italic>SR</italic> Sinus rhythm</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Marker levels in patients with sustained SR and discontinued warfarin treatment compared to reference group. P-values are derived from the Mann-Whitney <italic>U</italic>-test. Center lines show the medians; box limits indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles; whiskers extend 1.5 times the interquartile range from the 25<sup>th</sup> and 75<sup>th</sup> percentiles. Abbreviations: ETP, endogenous thrombin potential; F1&#x02009;+&#x02009;2, prothrombin fragment&#x000a0;1&#x02009;+&#x02009;2; SR, sinus rhythm</p></caption><graphic xlink:href="12959_2017_153_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par29">None of the markers were predictive of rhythm outcome 6 months after electrical cardioversion when dichotomised by median, baseline levels; D-dimer (log rank, <italic>p</italic>&#x02009;=&#x02009;0.849), ETP (log rank, <italic>p</italic>&#x02009;=&#x02009;0.423) and F1&#x02009;+&#x02009;2 (log rank, <italic>p</italic>&#x02009;=&#x02009;0.638). Kaplan-Meier analysis of quartiles of all three markers showed similar curves for survival free of AF for each quartile: D-dimer (log rank, <italic>p</italic>&#x02009;=&#x02009;0.750), ETP (log rank, <italic>p</italic>&#x02009;=&#x02009;0.346) and F1&#x02009;+&#x02009;2 (log rank, <italic>p</italic>&#x02009;=&#x02009;0.586).</p><p id="Par30">Treatment with candesartan had no impact on the levels of prothrombotic markers. ANCOVA analysis comparing the changes in prothrombotic markers from baseline to study end according to randomisation group showed no significant effects of candesartan (data not shown).</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par31">Sustained sinus rhythm for 6 months after electrical cardioversion for AF had no impact on levels of ETP, F1&#x02009;+&#x02009;2 or D-dimer. Furthermore, none of the markers were predictive of rhythm outcome after electrical cardioversion. However, discontinuation of warfarin treatment in a subset of 13 low-risk patients in sinus rhythm was associated with significantly higher levels of D-dimer and F1&#x02009;+&#x02009;2 compared to the reference group. Thus, AF patients maintain a hypercoagulable state despite restoration and maintenance of sinus rhythm 6 months after successful cardioversion.</p><p id="Par32">Angiotensin II may initiate a prothrombotic state by inducing inflammation, endothelial dysfunction and activation of platelets [<xref ref-type="bibr" rid="CR17">17</xref>]. Therefore, it is plausible that angiotensin II receptor blockers could influence on hypercoagulability. However, we found no effect of candesartan on levels of haemostatic markers in the present study.</p><p id="Par33">The prothrombotic markers remained unchanged after restoration and maintenance of sinus rhythm for 6 months in patients with continued warfarin treatment throughout the study. Other studies are in line with our findings. Li-Saw-Hee et al. investigated three different markers related to thrombogenicity; namely fibrinogen, P-selectin and von Willebrand factor, and observed no changes in these markers after 3 months maintenance of sinus rhythm following cardioversion [<xref ref-type="bibr" rid="CR18">18</xref>]. Another study reports unchanged levels of D-dimer, von Willebrand factor and soluble thrombomodulin 1 month after either spontaneous restoration of sinus rhythm or pharmacological cardioversion for acute onset AF without anticoagulation treatment [<xref ref-type="bibr" rid="CR19">19</xref>]. Hence, sustained sinus rhythm seems to have little impact on the hypercoagulable state associated with AF.</p><p id="Par34">We observed a rise in all three markers of hypercoagulability following discontinued warfarin treatment in 13 low-risk AF patients with sinus rhythm for 6 months. This observation is in line with previous reports of lowered levels of D-dimer, F1&#x02009;+&#x02009;2 and ETP by anticoagulation therapy [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Interestingly, we observed D-dimer and F1&#x02009;+&#x02009;2 to be significantly higher in low-risk AF patients in sinus rhythm for 6 months after cardioversion compared to a reference group without AF.</p><p id="Par35">Sustained sinus rhythm did not translate into lowered procoagulant activity in our material. These findings support current risk stratification schemes in which stroke risk in AF is considered independent of whether AF is categorised into paroxysmal, persistent and permanent forms [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Intriguingly, obtaining sinus rhythm may still be a therapeutic goal in itself, as lower risk of thromboembolism and death has been reported in paroxysmal AF forms [<xref ref-type="bibr" rid="CR25">25</xref>]. Moreover, the presence of sinus rhythm without antiarrhythmic drugs has been associated with reduced mortality [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. It is not clear whether the increased stroke risk associated with atrial tachyarrhythmias [<xref ref-type="bibr" rid="CR28">28</xref>] and rhythm shifts in AF [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>] is outbalanced by a lower risk during prolonged periods of sinus rhythm [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par36">D-dimer has been shown to predict thromboembolic events, and has an additional predictive value to clinical risk scores in patients with AF [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. However, none of the markers were predictive of rhythm outcome after electrical cardioversion in the present AF population. There were no differences in levels of ETP between AF patients maintaining sinus rhythm for 6 months and the reference group. Further studies are warranted to elucidate the relevance of ETP as a marker of hypercoagulability in AF patients.</p><sec id="Sec8"><title>Study limitations</title><p id="Par37">The present study was a substudy of the CAPRAF study, and not primarily designed to test the effects of sinus rhythm restoration on markers of thrombin generation or the predictive abilities of these markers in electrical cardioversion of AF, nor was long-term electrocardiogram monitoring conducted as part of this study. Hence we cannot exclude the possibility that some of the AF subjects in sinus rhythm or some of the subjects in the reference group had asymptomatic, paroxysmal AF. Because of small numbers and demographic differences between the reference group and AF patients, our results need confirmation in larger, prospective trials.</p></sec></sec><sec id="Sec9"><title>Conclusions</title><p id="Par38">Sustained sinus rhythm after electrical cardioversion of AF did not alter indices of hypercoagulability. In patients with AF and a low CHA<sub>2</sub>DS<sub>2</sub>-VASc score, discontinuation of oral anticoagulation was associated with a rise in D-dimer and F1&#x02009;+&#x02009;2 to levels significantly higher than in the reference group. Thus, our data support the current view of sustained hypercoagulability in AF patients despite long-term maintenance of sinus rhythm. Moreover, levels of prothrombotic markers were not associated with rhythm outcome after cardioversion.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE 1950 study</term><def><p id="Par6">Akershus Cardiac Examination 1950 study</p></def></def-item><def-item><term>AF</term><def><p id="Par7">Atrial fibrillation</p></def></def-item><def-item><term>CAPRAF study</term><def><p id="Par8">Candesartan in the prevention of relapsing atrial fibrillation study</p></def></def-item><def-item><term>CAT assay</term><def><p id="Par9">calibrated automated thrombogram assay</p></def></def-item><def-item><term>CHA<sub>2</sub>DS<sub>2</sub>-VASc score</term><def><p id="Par10">A measure of stroke risk in patients with atrial fibrillation, with scores ranging from 0 to 9 and higher scores indicating greater risk</p></def></def-item><def-item><term>ETP</term><def><p id="Par11">Endogenous thrombin potential</p></def></def-item><def-item><term>F1&#x02009;+&#x02009;2</term><def><p id="Par12">Prothrombin fragment&#x000a0;1&#x02009;+&#x02009;2</p></def></def-item><def-item><term>INR</term><def><p id="Par13">International normalised ratio</p></def></def-item><def-item><term>SR</term><def><p id="Par14">Sinus rhythm</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We thank CAPRAF co-investigator Irene Grundvold MD, PhD, study nurse Anne Kari Brun, RN, and study nurse Mona Olufsen, RN, B&#x000e6;rum Hospital, for excellent study conduct. We thank Vibeke Bratseth for laboratory analyses at Center for Clinical Heart Research at Department of Cardiology, Oslo University Hospital Ullev&#x000e5;l.</p><sec id="FPar1"><title>Funding</title><p id="Par39">This substudy was supported by Vestre Viken Hospital Trust. The original CAPRAF study was supported by the Regional Health Corporation of Eastern Norway, and the Medical Research Foundation, B&#x000e6;rum Hospital, Norway. AstraZeneca provided the study medication and covered the previous laboratory analyses.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par40">The dataset supporting the conclusions of this article is not publicly available, as the Data Protection Authority approval and patient consent do not allow for such publication.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AWH performed the data analyses and drafted the manuscript. IS carried out the laboratory analyses and participated in data interpretation. TB collected data and engaged in manuscript preparation. PS contributed to study design and interpretation of data. HA contributed to study design and interpretation of data. AT contributed to study design, coordination and data collection and in preparation of the manuscript. All authors have revised the manuscript for important intellectual content and have read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par41">The study was approved by the Regional Ethics Committee, and all patients provided written, informed consent in accordance with the revised Declaration of Helsinki.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par42">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par43">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par44">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Dawber</surname><given-names>TR</given-names></name><name><surname>Thomas</surname><given-names>HE</given-names><suffix>Jr</suffix></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group><article-title>Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study</article-title><source>Neurology</source><year>1978</year><volume>28</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1212/WNL.28.10.973</pub-id><pub-id pub-id-type="pmid">570666</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>T</given-names></name><name><surname>Shantsila</surname><given-names>E</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60040-4</pub-id><pub-id pub-id-type="pmid">19135613</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice</article-title><source>Pathophysiol Haemost Thromb</source><year>2003</year><volume>33</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1159/000083815</pub-id><pub-id pub-id-type="pmid">15692230</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Does atrial fibrillation confer a hypercoagulable state?</article-title><source>Lancet</source><year>1995</year><volume>346</volume><fpage>1313</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)92339-X</pub-id><pub-id pub-id-type="pmid">7475767</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>K</given-names></name><name><surname>Talwar</surname><given-names>S</given-names></name><name><surname>Copplestone</surname><given-names>A</given-names></name><name><surname>Gilbert</surname><given-names>TJ</given-names></name><name><surname>Haywood</surname><given-names>GA</given-names></name></person-group><article-title>Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin</article-title><source>Int J Cardiol</source><year>2004</year><volume>95</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2003.05.019</pub-id><pub-id pub-id-type="pmid">15159043</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giansante</surname><given-names>C</given-names></name><name><surname>Fiotti</surname><given-names>N</given-names></name><name><surname>Miccio</surname><given-names>M</given-names></name><name><surname>Altamura</surname><given-names>N</given-names></name><name><surname>Salvi</surname><given-names>R</given-names></name><name><surname>Guarnieri</surname><given-names>G</given-names></name></person-group><article-title>Coagulation indicators in patients with paroxysmal atrial fibrillation: effects of electric and pharmacologic cardioversion</article-title><source>Am Heart J</source><year>2000</year><volume>140</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1067/mhj.2000.108520</pub-id><pub-id pub-id-type="pmid">10966540</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Benussi</surname><given-names>S</given-names></name><name><surname>Kotecha</surname><given-names>D</given-names></name><name><surname>Ahlsson</surname><given-names>A</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Casadei</surname><given-names>B</given-names></name><name><surname>Castella</surname><given-names>M</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Heidbuchel</surname><given-names>H</given-names></name><name><surname>Hendriks</surname><given-names>J</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Manolis</surname><given-names>AS</given-names></name><name><surname>Oldgren</surname><given-names>J</given-names></name><name><surname>Popescu</surname><given-names>BA</given-names></name><name><surname>Schotten</surname><given-names>U</given-names></name><name><surname>Van Putte</surname><given-names>B</given-names></name><name><surname>Vardas</surname><given-names>P</given-names></name></person-group><article-title>2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><fpage>2893</fpage><lpage>2962</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw210</pub-id><pub-id pub-id-type="pmid">27567408</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spronk</surname><given-names>HM</given-names></name><name><surname>De Jong</surname><given-names>AM</given-names></name><name><surname>Verheule</surname><given-names>S</given-names></name><name><surname>De Boer</surname><given-names>HC</given-names></name><name><surname>Maass</surname><given-names>AH</given-names></name><name><surname>Lau</surname><given-names>DH</given-names></name><name><surname>Rienstra</surname><given-names>M</given-names></name><name><surname>van Hunnik</surname><given-names>A</given-names></name><name><surname>Kuiper</surname><given-names>M</given-names></name><name><surname>Lumeij</surname><given-names>S</given-names></name><name><surname>Zeemering</surname><given-names>S</given-names></name><name><surname>Linz</surname><given-names>D</given-names></name><name><surname>Kamphuisen</surname><given-names>PW</given-names></name><name><surname>Ten Cate</surname><given-names>H</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name><name><surname>Van Gelder</surname><given-names>IC</given-names></name><name><surname>van Zonneveld</surname><given-names>AJ</given-names></name><name><surname>Schotten</surname><given-names>U</given-names></name></person-group><article-title>Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>38</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw119</pub-id><pub-id pub-id-type="pmid">27071821</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohara</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Nozawa</surname><given-names>T</given-names></name><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Iwasa</surname><given-names>A</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>JD</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Hayano</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>K</given-names></name></person-group><article-title>Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation</article-title><source>Int J Cardiol</source><year>2008</year><volume>126</volume><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2007.06.020</pub-id><pub-id pub-id-type="pmid">17689760</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christersson</surname><given-names>C</given-names></name><name><surname>Wallentin</surname><given-names>L</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Alexander</surname><given-names>JH</given-names></name><name><surname>Ansell</surname><given-names>J</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Horowitz</surname><given-names>JD</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Husted</surname><given-names>S</given-names></name><name><surname>Hylek</surname><given-names>EM</given-names></name><name><surname>Lopes</surname><given-names>RD</given-names></name><name><surname>Siegbahn</surname><given-names>A</given-names></name></person-group><article-title>D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial</article-title><source>J Thromb Haemost</source><year>2014</year><volume>12</volume><fpage>1401</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1111/jth.12638</pub-id><pub-id pub-id-type="pmid">24942912</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vene</surname><given-names>N</given-names></name><name><surname>Mavri</surname><given-names>A</given-names></name><name><surname>Ko&#x00161;melj</surname><given-names>K</given-names></name><name><surname>Stegnar</surname><given-names>M</given-names></name></person-group><article-title>High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy</article-title><source>Thromb Haemost</source><year>2003</year><volume>90</volume><fpage>1163</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">14652652</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name></person-group><article-title>Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: a systematic review and meta-analysis</article-title><source>Can J Cardiol</source><year>2015</year><volume>31</volume><fpage>278</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2014.12.002</pub-id><pub-id pub-id-type="pmid">25746020</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tveit</surname><given-names>A</given-names></name><name><surname>Grundvold</surname><given-names>I</given-names></name><name><surname>Olufsen</surname><given-names>M</given-names></name><name><surname>Seljeflot</surname><given-names>I</given-names></name><name><surname>Abdelnoor</surname><given-names>M</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name></person-group><article-title>Candesartan in the prevention of relapsing atrial fibrillation</article-title><source>Int J Cardiol</source><year>2007</year><volume>120</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2006.08.086</pub-id><pub-id pub-id-type="pmid">17113170</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berge</surname><given-names>T</given-names></name><name><surname>Vigen</surname><given-names>T</given-names></name><name><surname>Pervez</surname><given-names>MO</given-names></name><name><surname>Ihle-Hansen</surname><given-names>H</given-names></name><name><surname>Lyngbakken</surname><given-names>MN</given-names></name><name><surname>Omland</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Steine</surname><given-names>K</given-names></name><name><surname>R&#x000f8;sj&#x000f8;</surname><given-names>H</given-names></name><name><surname>Tveit</surname><given-names>A</given-names></name></person-group><article-title>Heart and brain interactions - the Akershus cardiac examination (ACE) 1950 study design</article-title><source>Scand Cardiovasc J</source><year>2015</year><volume>49</volume><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">26364744</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemker</surname><given-names>HC</given-names></name><name><surname>Giesen</surname><given-names>P</given-names></name><name><surname>Al Dieri</surname><given-names>R</given-names></name><name><surname>Regnault</surname><given-names>V</given-names></name><name><surname>de Smedt</surname><given-names>E</given-names></name><name><surname>Wagenvoord</surname><given-names>R</given-names></name><name><surname>Lecompte</surname><given-names>T</given-names></name><name><surname>B&#x000e9;guin</surname><given-names>S</given-names></name></person-group><article-title>Calibrated automated thrombin generation measurement in clotting plasma</article-title><source>Pathophysiol Haemost Thromb</source><year>2003</year><volume>33</volume><fpage>4</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1159/000071636</pub-id><pub-id pub-id-type="pmid">12853707</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tveit</surname><given-names>A</given-names></name><name><surname>Bollmann</surname><given-names>A</given-names></name><name><surname>Seljeflot</surname><given-names>I</given-names></name><name><surname>Husser</surname><given-names>D</given-names></name><name><surname>Stridh</surname><given-names>M</given-names></name><name><surname>S&#x000f6;rnmo</surname><given-names>L</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Olsson</surname><given-names>SB</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name></person-group><article-title>Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation</article-title><source>Thromb Haemost</source><year>2009</year><volume>101</volume><fpage>601</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">19277431</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munger</surname><given-names>MA</given-names></name></person-group><article-title>Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions</article-title><source>PT</source><year>2011</year><volume>36</volume><fpage>22</fpage><lpage>40</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li-Saw-Hee</surname><given-names>FL</given-names></name><name><surname>Blann</surname><given-names>AD</given-names></name><name><surname>Gurney</surname><given-names>D</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function</article-title><source>Eur Heart J</source><year>2001</year><volume>22</volume><fpage>1741</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.1053/euhj.2000.2531</pub-id><pub-id pub-id-type="pmid">11511124</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mar&#x000ed;n</surname><given-names>F</given-names></name><name><surname>Rold&#x000e1;n</surname><given-names>V</given-names></name><name><surname>Climent</surname><given-names>VE</given-names></name><name><surname>Ib&#x000e1;&#x000f1;ez</surname><given-names>A</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>A</given-names></name><name><surname>Marco</surname><given-names>P</given-names></name><name><surname>Sogorb</surname><given-names>F</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation</article-title><source>Heart</source><year>2004</year><volume>90</volume><fpage>1162</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1136/hrt.2003.024521</pub-id><pub-id pub-id-type="pmid">15367514</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li-Saw-Hee</surname><given-names>FL</given-names></name><name><surname>Blann</surname><given-names>AD</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation</article-title><source>Stroke</source><year>2000</year><volume>31</volume><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1161/01.STR.31.4.828</pub-id><pub-id pub-id-type="pmid">10753983</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodin</surname><given-names>E</given-names></name><name><surname>Seljeflot</surname><given-names>I</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Hurlen</surname><given-names>M</given-names></name><name><surname>Appelbom</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>JB</given-names></name></person-group><article-title>Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment</article-title><source>Thromb Res</source><year>2009</year><volume>123</volume><fpage>573</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2008.03.018</pub-id><pub-id pub-id-type="pmid">18474393</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozawa</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Iwasa</surname><given-names>A</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Jong-dae</surname><given-names>L</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Hayano</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>K</given-names></name></person-group><article-title>Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation</article-title><source>Circ J</source><year>2004</year><volume>68</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1253/circj.68.29</pub-id><pub-id pub-id-type="pmid">14695462</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friberg</surname><given-names>L</given-names></name><name><surname>Hammar</surname><given-names>N</given-names></name><name><surname>Rosenqvist</surname><given-names>M</given-names></name></person-group><article-title>Stroke in paroxysmal atrial fibrillation: report from the Stockholm cohort of Atrial fibrillation</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn599</pub-id><pub-id pub-id-type="pmid">19176537</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Disertori</surname><given-names>M</given-names></name><name><surname>Franzosi</surname><given-names>MG</given-names></name><name><surname>Barlera</surname><given-names>S</given-names></name><name><surname>Cosmi</surname><given-names>F</given-names></name><name><surname>Quintarelli</surname><given-names>S</given-names></name><name><surname>Favero</surname><given-names>C</given-names></name><name><surname>Cappellini</surname><given-names>G</given-names></name><name><surname>Fabbri</surname><given-names>G</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Staszewsky</surname><given-names>L</given-names></name><name><surname>Moroni</surname><given-names>LA</given-names></name><name><surname>Latini</surname><given-names>R</given-names></name></person-group><article-title>Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial</article-title><source>BMC Cardiovasc Disord</source><year>2013</year><volume>13</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1186/1471-2261-13-28</pub-id><pub-id pub-id-type="pmid">23586654</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesan</surname><given-names>AN</given-names></name><name><surname>Chew</surname><given-names>DP</given-names></name><name><surname>Hartshorne</surname><given-names>T</given-names></name><name><surname>Selvanayagam</surname><given-names>JB</given-names></name><name><surname>Aylward</surname><given-names>PE</given-names></name><name><surname>Sanders</surname><given-names>P</given-names></name><name><surname>McGavigan</surname><given-names>AD</given-names></name></person-group><article-title>The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><fpage>1591</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw007</pub-id><pub-id pub-id-type="pmid">26888184</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corley</surname><given-names>SD</given-names></name><name><surname>Epstein</surname><given-names>AE</given-names></name><name><surname>DiMarco</surname><given-names>JP</given-names></name><name><surname>Domanski</surname><given-names>MJ</given-names></name><name><surname>Geller</surname><given-names>N</given-names></name><name><surname>Greene</surname><given-names>HL</given-names></name><name><surname>Josephson</surname><given-names>RA</given-names></name><name><surname>Kellen</surname><given-names>JC</given-names></name><name><surname>Klein</surname><given-names>RC</given-names></name><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Mickel</surname><given-names>M</given-names></name><name><surname>Mitchell</surname><given-names>LB</given-names></name><name><surname>Nelson</surname><given-names>JD</given-names></name><name><surname>Rosenberg</surname><given-names>Y</given-names></name><name><surname>Schron</surname><given-names>E</given-names></name><name><surname>Shemanski</surname><given-names>L</given-names></name><name><surname>Waldo</surname><given-names>AL</given-names></name><name><surname>Wyse</surname><given-names>DG</given-names></name></person-group><article-title>Relationships between sinus rhythm, treatment, and survival in the Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>1509</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000121736.16643.11</pub-id><pub-id pub-id-type="pmid">15007003</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>RJ</given-names></name><name><surname>McCready</surname><given-names>J</given-names></name><name><surname>Diab</surname><given-names>I</given-names></name><name><surname>Page</surname><given-names>SP</given-names></name><name><surname>Finlay</surname><given-names>M</given-names></name><name><surname>Richmond</surname><given-names>L</given-names></name><name><surname>French</surname><given-names>A</given-names></name><name><surname>Earley</surname><given-names>MJ</given-names></name><name><surname>Sporton</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Joseph</surname><given-names>JP</given-names></name><name><surname>Bashir</surname><given-names>Y</given-names></name><name><surname>Betts</surname><given-names>TR</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Staniforth</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Kistler</surname><given-names>P</given-names></name><name><surname>Rajappan</surname><given-names>K</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Schilling</surname><given-names>RJ</given-names></name></person-group><article-title>Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death</article-title><source>Heart</source><year>2012</year><volume>98</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2011-300720</pub-id><pub-id pub-id-type="pmid">21930724</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Healey</surname><given-names>JS</given-names></name><name><surname>Connolly</surname><given-names>SJ</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Israel</surname><given-names>CW</given-names></name><name><surname>Van Gelder</surname><given-names>IC</given-names></name><name><surname>Capucci</surname><given-names>A</given-names></name><name><surname>Lau</surname><given-names>CP</given-names></name><name><surname>Fain</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Bailleul</surname><given-names>C</given-names></name><name><surname>Morillo</surname><given-names>CA</given-names></name><name><surname>Carlson</surname><given-names>M</given-names></name><name><surname>Themeles</surname><given-names>E</given-names></name><name><surname>Kaufman</surname><given-names>ES</given-names></name><name><surname>Hohnloser</surname><given-names>SH</given-names></name></person-group><article-title>Subclinical atrial fibrillation and the risk of stroke</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>120</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1105575</pub-id><pub-id pub-id-type="pmid">22236222</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Botto</surname><given-names>GL</given-names></name><name><surname>Padeletti</surname><given-names>L</given-names></name><name><surname>Santini</surname><given-names>M</given-names></name><name><surname>Capucci</surname><given-names>A</given-names></name><name><surname>Gulizia</surname><given-names>M</given-names></name><name><surname>Ricci</surname><given-names>R</given-names></name><name><surname>Biffi</surname><given-names>M</given-names></name><name><surname>De Santo</surname><given-names>T</given-names></name><name><surname>Corbucci</surname><given-names>G</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>1768</fpage><lpage>1770</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.110.609297</pub-id><pub-id pub-id-type="pmid">21493904</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botto</surname><given-names>GL</given-names></name><name><surname>Padeletti</surname><given-names>L</given-names></name><name><surname>Santini</surname><given-names>M</given-names></name><name><surname>Capucci</surname><given-names>A</given-names></name><name><surname>Gulizia</surname><given-names>M</given-names></name><name><surname>Zolezzi</surname><given-names>F</given-names></name><name><surname>Favale</surname><given-names>S</given-names></name><name><surname>Molon</surname><given-names>G</given-names></name><name><surname>Ricci</surname><given-names>R</given-names></name><name><surname>Biffi</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name><name><surname>Vimercati</surname><given-names>M</given-names></name><name><surname>Corbucci</surname><given-names>G</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name></person-group><article-title>Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events</article-title><source>J Cardiovasc Electrophysiol</source><year>2009</year><volume>20</volume><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8167.2008.01320.x</pub-id><pub-id pub-id-type="pmid">19175849</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glotzer</surname><given-names>TV</given-names></name><name><surname>Daoud</surname><given-names>EG</given-names></name><name><surname>Wyse</surname><given-names>DG</given-names></name><name><surname>Singer</surname><given-names>DE</given-names></name><name><surname>Ezekowitz</surname><given-names>MD</given-names></name><name><surname>Hilker</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Qi</surname><given-names>D</given-names></name><name><surname>Ziegler</surname><given-names>PD</given-names></name></person-group><article-title>The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study</article-title><source>Circ Arrhythm Electrophysiol</source><year>2009</year><volume>2</volume><fpage>474</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1161/CIRCEP.109.849638</pub-id><pub-id pub-id-type="pmid">19843914</pub-id></element-citation></ref></ref-list></back></article>